BioAge Labs, Inc. (NASDAQ:BIOA) Stock Has Consensus Price Target of $33.00

Key Points

• Analyst sentiment is moderately positive: Six of eight analysts rate BioAge Labs a buy, while one rates it a hold and one a sell. The consensus 12-month price target is $33.00, though targets range from $8 to $40.
• The stock has declined sharply: BIOA opened at $5.10, near its 12-month low of $4.81, compared with a 12-month high of $25.95. Its 50-day and 200-day moving averages stand at $7.85 and $14.73, respectively.
• BioAge remains unprofitable but beat quarterly EPS estimates: The company reported a quarterly loss of $0.58 per share versus the expected $0.65 loss, alongside $2.45 million in revenue and a negative net margin exceeding 900%. Several hedge funds increased their positions or initiated new stakes during the second quarter.

Shares of BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $33.00.

A number of equities analysts recently weighed in on BIOA shares. Weiss Ratings lowered shares of BioAge Labs from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, October 8th. Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a research note on Friday, July 31st. Roth Capital restated a "buy" rating and issued a $25.00 price objective on shares of BioAge Labs in a report on Wednesday, September 9th. BTIG Research restated a "buy" rating and set a $40.00 price target on shares of BioAge Labs in a report on Tuesday, September 8th. Finally, UBS Group initiated coverage on shares of BioAge Labs in a report on Sunday, October 11th. They issued a "neutral" rating and a $8.00 price objective on the stock.

BioAge Labs Stock Performance

Shares of BIOA stock opened at $5.10 on Monday. The business's 50 day moving average is $7.85 and its two-hundred day moving average is $14.73. BioAge Labs has a 12-month low of $4.81 and a 12-month high of $25.95. The company has a market capitalization of $234.09 million, a P/E ratio of -2.14 and a beta of 1.08.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The business had revenue of $2.45 million during the quarter. On average, research analysts predict that BioAge Labs will post -2.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

Hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP acquired a new stake in shares of BioAge Labs during the second quarter worth $344,000. Squarepoint Ops LLC boosted its stake in shares of BioAge Labs by 23.3% during the 2nd quarter. Squarepoint Ops LLC now owns 68,436 shares of the company's stock worth $1,677,000 after acquiring an additional 12,916 shares in the last quarter. Corient Private Wealth LP grew its holdings in BioAge Labs by 76.7% in the second quarter. Corient Private Wealth LP now owns 40,258 shares of the company's stock valued at $987,000 after purchasing an additional 17,476 shares during the last quarter. Yiheng Capital Management L.P. purchased a new position in BioAge Labs during the 2nd quarter valued at about $4,180,000. Finally, Wellington Management Group LLP lifted its stake in BioAge Labs by 39.9% in the 2nd quarter. Wellington Management Group LLP now owns 94,656 shares of the company's stock valued at $2,320,000 after buying an additional 26,975 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.